+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy



Cost-effectiveness of growth factors during hepatitis C anti-viral therapy



Alimentary Pharmacology and Therapeutics 24(7): 1067-1077



Although the current standard of care for controlling anaemia and neutropenia during anti-viral therapy for hepatitis C is to use dose reduction of ribavirin and pegylated interferon, respectively, erythropoietin and granulocyte colony-stimulating factor are now being advocated as alternatives to dose reduction. To determine the cost-effectiveness of erythropoietin and granulocyte colony-stimulating factor as an alternative to anti-viral dose reduction during antihepatitis C therapy. Decision analysis was used to assess cost-effectiveness by estimating the cost of using a growth factor per quality-adjusted life-year gained. Under baseline assumptions, the cost per quality-adjusted life-year of using growth factors ranged from 16,247 US dollars for genotype 1 with neutropenia to 145,468 US dollars for genotype 2/3 patients with anaemia. These findings are sensitive to the relationship between dose reduction and sustained virological response. Based upon our findings and the varying strength of the evidence for a relationship between dose reduction and sustained virological response: granulocyte colony-stimulating factor may be cost-effective for genotype 1 patients; erythropoietin is probably not cost-effective for genotype 2/3 patients; no conclusion can be reached regarding the cost-effectiveness of erythropoietin for genotype 1 patients or granulocyte colony-stimulating factor for genotype 2/3 patients. Randomized trials are needed to firmly establish the relationship between dose reduction and sustained virological response.

(PDF emailed within 0-6 h: $19.90)

Accession: 011907300

Download citation: RISBibTeXText

PMID: 16984501

DOI: 10.1111/j.1365-2036.2006.03089.x


Related references

The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapeutics 42(3): 307-318, 2016

Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. American Journal of Transplantation 18(10): 2496-2505, 2018

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 44(6): 1598-1606, 2006

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Effectiveness and Resource Allocation 13: 21, 2015

The Cost Effectiveness Analysis Of The Oral Anti-Viral Treatments Alternatives For The Chronic Hepatitis B In Turkey. Value in Health 17(7): A367, 2014

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Alimentary Pharmacology and Therapeutics 44(8): 866-876, 2017

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics 27(12): 1240-1252, 2008

A Model of HIV Patient Care: Methods and Applications to the Cost-Effectiveness of Anti-Viral Therapy. Sexually Transmitted Diseases 27(10): 650-651, 2000

Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 97(1): 75-81, 2008

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis (vol 27, pg 1240, 2008). Alimentary Pharmacology and Therapeutics 28(1): 166, 2007

Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation 101(5): 1001-1008, 2016

Relationship between hepatitis b virus specific dna polymerase and hepatitis b e antigen antibody system in chronic hepatitis b virus infection factors determining selection of patients and outcome of anti viral therapy. Gut 24(2): 143-147, 1983

Detection of Hepatitis C Antibodies Without Viral Transmission in Hepatitis C-Negative Recipients Receiving Kidneys From Hepatitis C-Positive Donors Treated With Direct-Acting Antiviral Therapy. Transplantation 102(3): E121-E122, 2017

The decision to begin Highly Active Anti-Retroviral Therapy in patients with low viral loads A cost-effectiveness analysis. JGIM 14(SUPPL 2): 100, April, 1999

Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Economics 19(5): 518-531, 2010